These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 12110039

  • 1. Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure.
    Maxwell AP.
    Kidney Int; 2002 Aug; 62(2):720-9. PubMed ID: 12110039
    [No Abstract] [Full Text] [Related]

  • 2. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G.
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [Abstract] [Full Text] [Related]

  • 3. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW, Haley NR, Adamson JW.
    Contrib Nephrol; 1990 Oct; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Erythropoiesis-stimulating agents in kidney and cardiac disease.
    Fluck R.
    Br J Hosp Med (Lond); 2006 Oct; 67(10):533-7. PubMed ID: 17069130
    [No Abstract] [Full Text] [Related]

  • 6. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS.
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The new label for erythropoiesis stimulating agents: the FDA'S sentence.
    Fishbane S, Jhaveri KD.
    Semin Dial; 2012 May; 25(3):263-6. PubMed ID: 22515844
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF, Casanova-González M, García-García I, Porrero-Martín PJ, Valenzuela-Silva CM, Hernández-Montero T, Lagarde-Ampudia M, Casanova-Kutsareva Y, Avila-Albuerne Y, Vargas-Batista A, Bobillo-López H, Herrera-Valdés R, López-Saura PA, Bioequivalence Study of Erythropoietin Group.
    BMC Nephrol; 2005 May 23; 6():5. PubMed ID: 15910687
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
    Arenas Gracia M, Abad Gosálvez A, Colomina Avilés J, Pascual Pérez R, Ferriz Moreno P.
    An Med Interna; 1995 Apr 23; 12(4):187-8. PubMed ID: 7620064
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.